Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder
In this real-world database analysis, patients with BP-I who initiated cariprazine as their first AA had lower rates of HRU and incurred lower costs than patients who initiated cariprazine as a subsequent AA.
Authors
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Sean D. MacKnight (ORCID: https://orcid.org/0000-0001-5032-2110)
- Julien Boudreau
- Guillaume Germain (ORCID: https://orcid.org/0000-0002-4525-7673)
- Andrew J. Cutler (ORCID: https://orcid.org/0000-0001-5800-0378)
- Mousam Parikh
- Sally Wade
Institutions
- Outcomes Research Consortium (US)
- SUNY Upstate Medical University (US)
- AbbVie (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1080/13696998.2024.2419721
- Citations
- 2
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- AbbVie Canada